Future Therapeutic Directions for the Treatment of PsoriasisR.B. Warren; C.E.M. Griffiths · 2009

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centreR.B. Warren; B.C. Brown; D. Lavery; C.E.M. Griffiths · 2010

Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapyH.L. Hébert; F.R. Ali; J. Bowes; C.E.M. Griffiths; A. Barton; R.B. Warren · 2012

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centreR.B. Warren; B.C. Brown; D. Lavery; D.M. Ashcroft; C.E.M. Griffiths · 2009

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphismsR.B. Warren; R.L. Smith; E. Campalani; S. Eyre; C.H. Smith; J.N.W.N. Barker; J. Worthington; C.E.M. Griffiths · 2009

Polymorphisms in the PTPN22 region are associated with psoriasis of early onsetRh.Ll. Smith; R.B. Warren; S. Eyre; X. Ke; H.S. Young; M. Allen; D. Strachan; W. McArdle; M.P. Gittins; J.N.W.N. Barker; C.E.M. Griffiths; J. Worthington · 2008

The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectivesA.D. Burden; R.B. Warren; C.E. Kleyn; K. McElhone; C.H. Smith; N.J. Reynolds; A.D. Ormerod; C.E.M. Griffiths; on behalf of the BADBIR Study Group · 2012